Revolution Medicines (RVMD) stock slips in premarket as AbbVie denies takeover talks, deal buzz lingers
New York, Jan 8, 2026, 05:22 EST — Premarket Shares of Revolution Medicines fell 9.8% to $92.60 in premarket trading on Thursday, pulling back after a sharp, rumor-driven run-up in the prior session. Investing.com The whipsaw started after the Wall Street Journal reported AbbVie was in advanced discussions to buy the cancer-drug developer, a deal that could value Revolution at about $20 billion, including a typical takeover premium — the extra paid above the market price. The Journal also said other bidders could be in the mix. The Wall Street Journal AbbVie later said it was not in discussions with